Myriad Genetics Reports Fiscal Second-Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Mizuho Securities Remains Neutral on Myriad Genetics (MYGN); Awaiting Reimbursement Progress
February 3, 2016 8:07 AM ESTMizuho Securities reiterated a Neutral rating and $42.00 price target on Myriad Genetics (NASDAQ: MYGN) following the company's 2Q earnings report. MYGN beat consensus revenues by $5mm and EPS by $0.04. However, Mizuho remains sidelined until more progress on reimbursement is seen.
Analyst Eric Criscuolo... More
Myriad Genetics (MYGN) Tops Q2 EPS by 4c
February 2, 2016 4:06 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.45, $0.04 better than the analyst estimate of $0.41. Revenue for the quarter came in at $193.3 million versus the consensus estimate of $189.97 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
... More